CLINICAL PHARMACOLOGY
Following administration of 100 mg twice daily for three consecutive days, plasma levels of VERMOX® (mebendazole) and its primary metabolite, the 2-amine, do not exceed 0.03 µg/ml and 0.09 µg/ml, respectively. All metabolites are devoid of anthelmintic activity. In man, approximately 2% of administered VERMOX® is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite.
Mode of Action: VERMOX® inhibits the formation of the worms' microtubules and causes the worms' glucose depletion.
|
